Samsung Bioepis selected Yuhan Corporation as a domestic sales company of Humira’s biosimilar’Adaloce’

Samsung Bioepis announced on the 15th that it has selected Yuhan Corporation as the domestic sales company of Humira’s biosimilar,’Adaloce (ingredient name adalidomab)’, a rheumatoid arthritis treatment.

Adaloce is the first product in Korea to be approved for sale as a Humira biosimilar, the world’s No. 1 drug product in sales. It is a treatment for autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease, whose mechanism is to suppress the expression of tumor necrosis factor-alpha in the body.

Samsung Bioepis has been preparing for launch through a licensing agreement with ABBVIE after acquiring the domestic sales license of Adaloche in September 2017.

Prior to the launch of Adaloce, which was planned in the first half of this year, Samsung Bioepis conducted consultations with a number of companies to select a marketing partner, and finally selected Yuhan Corporation as a sales company.

As a result, Samsung Bioepis will sell all biosimilar products in the domestic tumor necrosis factor-alpha inhibitors (Humira, Enbrel, and Remicade) worth about 200 billion won.

Adaloce was launched in October 2018 under the product name’Imraldi’ in the European market. By the end of last year, it achieved cumulative product sales of $417 million (about 450 billion won).

In the U.S. market, in May 2019, it obtained a marketing license under the product name’Hardlima’, and is planning to launch it in July 2023 according to a licensing agreement with AbbVie.

In addition, Samsung Bioepis is also conducting domestic sales of Etoloche (Enbrel Biosimilar) and Remaroche (Remicade Biosimilar), which were previously launched autoimmune diseases, through Yuhan Corporation.

Han-Seung Ko, President of Samsung Bioepis said, “We are pleased to be able to introduce biosimilar products of the world’s most widely used drugs in Korea.” I will do it.”